Last reviewed · How we verify
alpha-GI
Alpha-glucosidase inhibitor that slows carbohydrate digestion and glucose absorption in the small intestine.
Alpha-glucosidase inhibitor that slows carbohydrate digestion and glucose absorption in the small intestine. Used for Type 2 diabetes mellitus, Impaired glucose tolerance.
At a glance
| Generic name | alpha-GI |
|---|---|
| Sponsor | Sanofi |
| Drug class | Alpha-glucosidase inhibitor |
| Target | Alpha-glucosidase enzymes (intestinal brush border) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Alpha-GI drugs inhibit enzymes (alpha-glucosidases) responsible for breaking down disaccharides and complex carbohydrates into monosaccharides. By delaying glucose absorption, they reduce postprandial blood glucose spikes in patients with type 2 diabetes or impaired glucose tolerance. This mechanism helps improve glycemic control without stimulating insulin secretion.
Approved indications
- Type 2 diabetes mellitus
- Impaired glucose tolerance
Common side effects
- Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)
- Abdominal pain
- Nausea
Key clinical trials
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (PHASE1, PHASE2)
- Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (PHASE2)
- GI Alpha-Gal Study (NA)
- RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System (NA)
- Novel Alpha Glucan GI Tolerability Study (Loris Chronic) (NA)
- Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth (EARLY_PHASE1)
- Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha-GI CI brief — competitive landscape report
- alpha-GI updates RSS · CI watch RSS
- Sanofi portfolio CI